摘要
马兴田从广东省普宁市一个小山村起步,以药起家,将康美药业做到干亿市值,然而仅仅一年间,爆发出的财务丑闻以及行贿的黑历史,让公司从千亿白马极速坠落到退市边缘,康美药业是如何崩塌的?面对证监会的调查结果,康美药业还是没有彻底'认错'。
In the face of the investigation results of the China Securities Regulatory Commission,Kangmei Pharmaceutical has not completely'accepted the mistake'.Compared with the plunging stock price,the mystery surrounding Kangmei Pharmaceutical is even more shocking.Kangmei Pharmaceutical and Guangzhou Zhengzhong Zhujiang Accounting Firm,which is responsible for financial auditing,are all under investigation.Kangmei Pharmaceutical and its founder Ma Xingtian will face even more severe penalties,and delisting may also be an option for punishment.From a small pharmaceutical factory in Guangdong Province to an A-share star with a market value of 100 billion yuan,and then to the worry of delisting,what has Kangmei Pharmaceutical and Ma Xingtian experienced?
出处
《中国企业家》
2019年第7期120-125,7,共7页
China Entrepreneur